HC Wainwright reissued their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST - Free Report) in a research note published on Monday, Benzinga reports. They currently have a $25.00 price target on the stock.
Separately, Rodman & Renshaw initiated coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They set a buy rating and a $9.00 target price on the stock.
Get Our Latest Analysis on MIST
Milestone Pharmaceuticals Trading Up 2.1 %
Shares of Milestone Pharmaceuticals stock traded up $0.03 on Monday, hitting $1.48. 66,417 shares of the company traded hands, compared to its average volume of 203,968. The company has a current ratio of 19.13, a quick ratio of 19.13 and a debt-to-equity ratio of 1.61. The company has a market cap of $78.82 million, a PE ratio of -1.18 and a beta of 1.72. The stock's 50 day moving average price is $1.46 and its 200-day moving average price is $1.53. Milestone Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $3.52.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. Equities research analysts predict that Milestone Pharmaceuticals will post -0.71 EPS for the current year.
Institutional Investors Weigh In On Milestone Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in MIST. BNP Paribas Financial Markets lifted its position in shares of Milestone Pharmaceuticals by 177.0% during the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company's stock valued at $30,000 after buying an additional 10,800 shares during the last quarter. Lion Point Capital LP lifted its position in Milestone Pharmaceuticals by 1.7% during the second quarter. Lion Point Capital LP now owns 2,340,207 shares of the company's stock valued at $3,089,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Valeo Financial Advisors LLC boosted its stake in Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company's stock valued at $30,000 after acquiring an additional 10,000 shares in the last quarter. Institutional investors own 86.18% of the company's stock.
Milestone Pharmaceuticals Company Profile
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Read More
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
